

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/256962 A1

(51) International Patent Classification:

C12N 15/67 (2006.01) A61K 39/00 (2006.01)
C07K 14/245 (2006.01) C12P 19/34 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2024/055699

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

11 June 2024 (11.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,060 14 June 2023 (14.06.2023) US
63/610,042 14 December 2023 (14.12.2023) US
63/649,495 20 May 2024 (20.05.2024) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **PFIZER INC.**, [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **BENNETT, Eric Matthew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **DON-ALD, Robert George Konrad**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **LIN LOHSE, Laura**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **SILMON DE MON-ERRI, Natalie Clare**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHOD FOR STABILIZING RNA

(57) Abstract: The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

WO 2024/256962 A1